Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, July 29, 2024
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
Thursday, July 25, 2024
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration
Tuesday, July 23, 2024
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024
Friday, July 12, 2024
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel
Thursday, July 11, 2024
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong
Tuesday, July 2, 2024
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC)
Friday, June 28, 2024
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China
Friday, June 21, 2024
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City
Monday, June 10, 2024
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Monday, June 3, 2024
Eisai Named to List of The Time 100 Most Influential Companies

Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: